Q-omics provides the consensus-scored PHF20 profile across patient tissues and cancer cell-line models. PHF20 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PHF20 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PHF20 RNA expression shows 20,304 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where PHF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHF20 survival associations across molecular data types. PHF20 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHF20 RNA expression–survival associations across cancer types. High PHF20 expression shows unfavorable associations in MESO, KICH, LIHC and BLCA, but favorable associations in UCS and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for PHF20 RNA expression.
This table summarizes PHF20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PHF20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHF20 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, KIRP and STAD. The HNSC box plot shows higher PHF20 RNA expression in tumor versus normal tissue (log2 FC = +0.677, t-test p < 0.001).
This table shows molecular features associated with PHF20 in patient tissues and cancer cell lines. In patient samples, PHF20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PHF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
